多囊卵巢综合征诊断的发病率、患病率及趋势:2006年至2019年美国基于人群的研究
该研究基于美国Kaiser Permanente Washington 2006年至2019年的回顾性队列,纳入177,527名女性,识别2491例新发多囊卵巢综合征(PCOS),总发病率为42.5/10,000人年,2019年患病率为5.2%。16至20岁人群发病率从31.0升至51.9/10,000人年(P=.01),26至30岁人群从82.8降至45.0/10,000人年(P=.02)。
要点
- PCOS总发病率为42.5/10,000人年,约为英国报告的4至5倍。
- 2019年患病率为5.2%,夏威夷及太平洋岛民组最高(7.6%)。
- 16至20岁发病率上升(31.0至51.9/10,000人年,P=.01),26至30岁下降(82.8至45.0/10,000人年,P=.02)。
核心结论
- 在美国非选择女性队列中,PCOS新诊断率随时间保持稳定。
- PCOS发病率约为英国报告的4至5倍,患病率(5.2%)几乎是基于ICD编码的美国已发表估计值(2.9%)的两倍。
- 种族和民族及诊断提供者类型似乎对时间趋势率没有重大影响。
- 年轻组新诊断随时间增加而年长组减少,可能与实践模式转变、对PCOS长期健康影响的认识提高及预防改善有关,肥胖率增加也可能是诊断年龄提前的因素。
研究设计与样本
- 美国Kaiser Permanente Washington 2006年至2019年回顾性队列研究。
- 纳入标准为女性、年龄16至40岁、入组至少3年且期间至少1次医疗就诊。
- 排除有卵巢切除或子宫切除史者,以及研究入组前已诊断PCOS者(用于发病率估计)。
- PCOS病例通过ICD-9 256.4或ICD-10 E28.2诊断编码识别。
- 对2011年至2019年诊断的700例新发病例进行病历审查,以Rotterdam标准验证ICD编码识别的新发病例。
主要发现
- 177,527名合格患者贡献586,470人年,识别2491例新发PCOS病例。
- 诊断时平均年龄26.9岁,平均体重指数31.6 kg/m2。
- 总发病率为42.5/10,000人年;16至20岁人群从31.0升至51.9/10,000人年(P=.01),26至30岁人群从82.8降至45.0/10,000人年(P=.02)。
- 仅在非西班牙裔白人中发现发病率有小幅下降趋势(P=.01)。
- 2019年58,241名贡献人时的患者中,3036名(5.2%)有PCOS的ICD诊断编码;患病率在夏威夷及太平洋岛民组最高(7.6%),其次是美洲原住民和西班牙裔组。
关键数值与推荐
- PCOS病例定义采用ICD-9 256.4或ICD-10 E28.2诊断编码。
- 病历审查验证采用Rotterdam标准。
- 发病率按2010年美国人口普查数据直接标准化进行年龄调整。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polycystic ovary syndrome is the most common endocrine disorder in women of reproductive age, yet US incidence estimates do not exist, and prevalence estimates vary widely. OBJECTIVE: A population-based US study estimated the incidence, prevalence, and trends of polycystic ovary syndrome by age, race and ethnicity, and diagnosing provider type. STUDY DESIGN: A retrospective cohort study of patients enrolled in Kaiser Permanente Washington from 2006 to 2019 was conducted. All members identified as female, aged 16 to 40 years with at least 3 years of enrollment and at least 1 healthcare encounter during that time, were eligible for inclusion. Individuals were excluded if they had a history of oophorectomy or hysterectomy. Polycystic ovary syndrome cases were identified using the International Classification of Diseases diagnosis codes (International Classification of Diseases, Ninth Revision, 256.4 or International Classification of Diseases, Tenth Revision, E28.2). Individuals with a polycystic ovary syndrome diagnosis before study entry were excluded from incidence rate estimations. The incidence rates were adjusted by age using direct standardization to the 2010 US census data. Temporal trends in incidence were assessed using weighted linear regression (overall) and Poisson regression (by age, race and ethnicity, and provider type). Prevalent cases were defined as patients with a polycystic ovary syndrome diagnosis at any time before the end of 2019. Medical record review of 700 incident cases diagnosed in 2011-2019 was performed to validate incident cases identified by International Classification of Diseases codes using the Rotterdam criteria. RESULTS: Among 177,527 eligible patients who contributed 586,470 person-years, 2491 incident polycystic ovary syndrome cases were identified. The mean age at diagnosis was 26.9 years, and the mean body mass index was 31.6 kg/m2. Overall incidence was 42.5 per 10,000 person-years; the rates were similar over time but increased in individuals aged 16 to 20 years from 31.0 to 51.9 per 10,000 person-years (P=.01) and decreased among those aged 26 to 30 years from 82.8 to 45.0 per 10,000 person-years (P=.02). A small decreasing temporal trend in incidence rates was only observed among non-Hispanic White individuals (P=.01). The incidence rates by diagnosing provider type varied little over time. Among the 58,241 patients who contributed person-time in 2019, 3036 (5.2%) had a polycystic ovary syndrome International Classification of Diseases diagnosis code; the prevalence was the highest among the Hawaiian and Pacific Islander group (7.6%) followed by Native American and Hispanic groups. Medical record review classified 60% as definite or probable incident, 14% as possible incident, and 17% as prevalent polycystic ovary syndrome. The overall positive predictive value of polycystic ovary syndrome International Classification of Diseases diagnosis code for identifying definite, probable, or possible incident polycystic ovary syndrome was 76% (95% confidence interval, 72%-79%). CONCLUSION: Among a cohort of nonselected females in the United States, we observed stable rates of incident polycystic ovary syndrome diagnoses over time. The incidence of polycystic ovary syndrome was 4- to 5-fold greater than reported for the United Kingdom. The prevalence of polycystic ovary syndrome (5.2%) was almost double before the published US estimates (2.9%) based on the International Classification of Diseases codes. Race and ethnicity and provider type did not seem to have a major impact on temporal rates. Incident diagnoses increased over time in younger and decreased in older age groups, perhaps related to shifting practice patterns with greater awareness among practitioners of the impact of polycystic ovary syndrome on long-term health outcomes and improved prevention efforts. Moreover, increasing obesity rates may be a factor driving the earlier ages at diagnosis.
引用
- Yu O, Christ JP, Schulze-Rath R, et al. Incidence, prevalence, and trends in polycystic ovary syndrome diagnosis: a United States population-based study from 2006 to 2019. Am J Obstet Gynecol. 2023. PMID: 37061077. doi:10.1016/j.ajog.2023.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。